Smith K J, Hodges P A
Transfusion. 1984 Nov-Dec;24(6):520-3. doi: 10.1046/j.1537-2995.1984.24685066816.x.
Cryoprecipitate is used infrequently in home therapy for patients with hemophilia A since freezer storage is required and resuspension and pooling of thawed cryoprecipitate is cumbersome. We evaluated procedures for preparation of cryoprecipitate in an "open system" so that four to six bags of cryoprecipitate could be pooled after production and refrozen for home therapy. Factor VIII activity for pooled cryoprecipitate was 132 +/- 30 (mean +/- SD), 125 +/- 45, and 145 +/- 47 units per bag pooled in three separate studies. Cultures from cryoprecipitate pools and individual cryoprecipitate bags did not show contamination in the "open system" or with the water bath thawing procedure. The mean increment in factor VIII activity per unit per kg infused was 0.02 units per ml and the mean half-life was 10.5 hours in three patients with hemophilia A. Pooled cryoprecipitate was shown to be clinically efficacious and acceptable for use in home care programs for hemophilia A.
冷沉淀很少用于甲型血友病患者的家庭治疗，因为需要冷冻保存，且解冻后的冷沉淀重悬和汇集操作繁琐。我们评估了在“开放系统”中制备冷沉淀的程序，以便在生产后将四至六袋冷沉淀汇集起来并重新冷冻用于家庭治疗。在三项独立研究中，汇集冷沉淀的 VIII 因子活性分别为每袋汇集物 132±30（均值±标准差）、125±45 和 145±47 单位。冷沉淀汇集物和单个冷沉淀袋的培养物在“开放系统”或水浴解冻程序中均未显示污染。在三名甲型血友病患者中，每输注每千克体重每单位 VIII 因子活性的平均增加值为每毫升 0.02 单位，平均半衰期为 10.5 小时。结果表明，汇集冷沉淀在甲型血友病家庭护理项目中临床有效且可接受。
